NFE2L2 and diabetes mellitus: In STZ-injected mice, epigallocatechin gallate (EGCG) prevented diabetes-induced kidney damage by upregulating Nrf2 expression, which was mediated by disrupting the Nrf2-Keap1 complex [120].